The Food and Drug Administration (FDA) has approved Emblaveoâ„¢ (aztreonam and avibactam), in combination with metronidazole, for patients 18 years and older who have limited or no alternative ...
Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be approved by the FDA for complicated intra-abdominal infections with limited ...
AbbVie announced that the US Food and Drug Administration (FDA) has approved Emblaveo (aztreonam and avibactam), as the first and only fixed-dose, intravenous, monobactam/ß-lactamase inhibitor ...
Hosted on MSN1mon
AbbVie gets FDA approval for antibiotic treatment Emblaveo (update)AbbVie (NYSE:ABBV) said it has received FDA approval for the intravenous antibiotic treatment Emblaveo, which was co-developed with Pfizer (NYSE:PFE). The FDA approved Emblaveo, a combination of ...
AbbVie's combination antibiotic Emblaveo has gotten federal approval to treat complicated intra-abdominal infections, making it the first and only such therapy approved to fight antimicrobial ...
NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEOâ„¢ (aztreonam and avibactam) for the treatment of adults with complicated intra-abdominal infections (cIAI ...
Approval of this indication is based on limited clinical safety and efficacy data for Emblaveo. In REVISIT, study participants with cIAI (n=312) were randomly assigned 2:1 to receive aztreonam ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback